Nuclear Medicine Journal Previews: Feb 13, 2026

New research published ahead-of-print by The Journal of Nuclear Medicine (JNM)

Published on Feb. 14, 2026

Got story updates? Submit your updates here. ›

The Journal of Nuclear Medicine (JNM) has published new research ahead-of-print, including studies on targeted radiation therapy for colorectal cancer, radioactive trastuzumab for HER2-positive breast cancer, imaging to predict response to prostate cancer therapy, a new brain scan tracer, simplified brain PET imaging, and advanced imaging for high-risk prostate cancer surgery.

Why it matters

These studies showcase the latest advancements in nuclear medicine and molecular imaging, which are enabling more precise, personalized, and effective treatments for various types of cancer. The research has the potential to improve outcomes and quality of life for patients.

The details

The new JNM studies cover a range of topics, including: a targeted radiation therapy approach for colorectal cancer using paired lead isotopes and engineered antibodies; a radioactive form of trastuzumab for HER2-positive breast cancer; imaging patterns that could help predict response to targeted prostate cancer therapy; a new PET brain scan tracer to measure microtubule activity; simplified analysis methods for a PET tracer that measures synaptic density and brain blood flow; and the use of advanced PSMA PET/CT scans to improve outcomes in high-risk prostate cancer surgery. Additionally, a new clinical trial is evaluating repeat targeted radiation therapy for advanced prostate cancer patients.

  • The new research articles were published ahead-of-print by The Journal of Nuclear Medicine on February 13, 2026.

The players

The Journal of Nuclear Medicine (JNM)

JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics.

Got photos? Submit your photos here. ›

The takeaway

The new research published in JNM showcases the rapid advancements in nuclear medicine and molecular imaging, which are enabling more personalized and effective cancer treatments. These studies have the potential to significantly improve outcomes and quality of life for patients across various cancer types.